These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Vaccine adjuvant systems: enhancing the efficacy of sub-unit protein antigens. Perrie Y; Mohammed AR; Kirby DJ; McNeil SE; Bramwell VW Int J Pharm; 2008 Dec; 364(2):272-80. PubMed ID: 18555624 [TBL] [Abstract][Full Text] [Related]
23. Innate immunity and new adjuvants. Mutwiri G; Gerdts V; Lopez M; Babiuk LA Rev Sci Tech; 2007 Apr; 26(1):147-56. PubMed ID: 17633299 [TBL] [Abstract][Full Text] [Related]
24. New developments in vaccine research--unveiling the secret of vaccine adjuvants. de Veer M; Meeusen E Discov Med; 2011 Sep; 12(64):195-204. PubMed ID: 21955847 [TBL] [Abstract][Full Text] [Related]
25. Defending the mucosa: adjuvant and carrier formulations for mucosal immunity. Lawson LB; Norton EB; Clements JD Curr Opin Immunol; 2011 Jun; 23(3):414-20. PubMed ID: 21511452 [TBL] [Abstract][Full Text] [Related]
26. Biomaterials as vaccine adjuvants. Jones KS Biotechnol Prog; 2008; 24(4):807-14. PubMed ID: 19194892 [TBL] [Abstract][Full Text] [Related]
27. Immunity in response to particulate antigen-delivery systems. Storni T; Kündig TM; Senti G; Johansen P Adv Drug Deliv Rev; 2005 Jan; 57(3):333-55. PubMed ID: 15560945 [TBL] [Abstract][Full Text] [Related]
31. Mucosal Vaccine Development Based on Liposome Technology. Bernasconi V; Norling K; Bally M; Höök F; Lycke NY J Immunol Res; 2016; 2016():5482087. PubMed ID: 28127567 [TBL] [Abstract][Full Text] [Related]
32. Designing the Next Generation of Vaccines: Relevance for Future Pandemics. Domínguez-Andrés J; van Crevel R; Divangahi M; Netea MG mBio; 2020 Dec; 11(6):. PubMed ID: 33443120 [TBL] [Abstract][Full Text] [Related]
33. Beyond adjuvants: Antagonizing inflammation to enhance vaccine immunity. Alter G; Sekaly RP Vaccine; 2015 Jun; 33 Suppl 2():B55-9. PubMed ID: 26022570 [TBL] [Abstract][Full Text] [Related]
34. Vaccine Ingredients: Components that Influence Vaccine Efficacy. Kocourkova A; Honegr J; Kuca K; Danova J Mini Rev Med Chem; 2017; 17(5):451-466. PubMed ID: 27488583 [TBL] [Abstract][Full Text] [Related]
35. New generation of mucosal adjuvants for the induction of protective immunity. Yuki Y; Kiyono H Rev Med Virol; 2003; 13(5):293-310. PubMed ID: 12931340 [TBL] [Abstract][Full Text] [Related]
37. New insights in mucosal vaccine development. Pavot V; Rochereau N; Genin C; Verrier B; Paul S Vaccine; 2012 Jan; 30(2):142-54. PubMed ID: 22085556 [TBL] [Abstract][Full Text] [Related]
38. Toll or toll-free adjuvant path toward the optimal vaccine development. Ishii KJ; Akira S J Clin Immunol; 2007 Jul; 27(4):363-71. PubMed ID: 17370119 [TBL] [Abstract][Full Text] [Related]
39. Current adjuvants and new perspectives in vaccine formulation. Montomoli E; Piccirella S; Khadang B; Mennitto E; Camerini R; De Rosa A Expert Rev Vaccines; 2011 Jul; 10(7):1053-61. PubMed ID: 21806399 [TBL] [Abstract][Full Text] [Related]